For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on January 4th, 2023 | 07:17 CET
Takeover fever 2023? BioNTech, Barrick Gold, Standard Lithium, Manuka Resources
The pharmaceutical sector was already in takeover fever last year. BioNTech partner Pfizer, among others, made several acquisitions. The hunger for acquisitions is likely to continue in the current year as major pharmaceutical and biotech companies are looking to fill up their pipelines. The current year could also be exciting for gold stocks. In 2022, companies failed to keep pace with the positive gold price. Producers of raw materials for the energy transition could also get into takeover fever. Manuka Resources could benefit from the latest two trends. The Canadians have just carried out a capital measure to advance their projects. Corporations could also target specialists like Standard Lithium. Rumours that Tesla is looking at lithium projects have been doing the rounds for a long time. And what about Barrick Gold and BioNTech?
Read
Commented by Fabian Lorenz on December 28th, 2022 | 08:05 CET
Outperformer stocks in 2023? BioNTech, Steinhoff, Saturn Oil + Gas, K+S
Will energy stocks continue to be outperformers in 2023? In any case, in 2022, MSCI World Energy clearly outperformed MSCI World. In the case of individual stocks, Shell, for example, has gained over 45% in the current year. Jefferies recommends the stock as a buy with a target price of GPX 3100 (pence). Warren Buffett has also invested billions in the oil sector in 2022. Chevron and Occidental Petroleum are among Berkshire Hathaway's seven largest holdings. Energy, after all, is likely to be in demand in 2023. Those looking to bet on a laggard should look at Saturn Oil & Gas. The Canadian oil producer faces a milestone in 2023, and analysts see over 200% upside potential. BioNTech enters the new year with solid newsflow. And what is Steinhoff doing after the horror news?
Read
Commented by Fabian Lorenz on December 27th, 2022 | 06:07 CET
Excitement at BASF, Nel ASA, Meta Materials: Shares for 2023
After a difficult 2022, investors are looking ahead to the coming year. In 2023, it will be important to pick the right stocks again because there will be winners - despite the war in Ukraine, high inflation and rising interest rates. At the same time, the price rockets of the old year are rarely also those of the new year. As is well known, BASF shares have struggled in 2022. If energy prices continue to ease, the high dividend yield, among other things, will entice investors. Also, there is news in the electromobility megamarket. There is no question that hydrogen offers huge opportunities worldwide. But companies like Nel and Plug Power must finally wake up faster and reduce losses. At Nel ASA, a sell recommendation weighed on the share price at the end of the year. Hot stock Meta Materials has already multiplied sales in the first 3 quarters of 2022, and the chances are good that the positive trend will continue in 2023. Then the Meta Materials share should also take off.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read
Commented by Fabian Lorenz on December 19th, 2022 | 13:57 CET
BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?
Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.
Read
Commented by Fabian Lorenz on December 15th, 2022 | 12:05 CET
E-car boom in Germany: BYD, Plug Power and dynaCERT are profiteers of the energy transition
The trend toward e-cars continues. In November 2022, 260,512 passenger cars were newly registered in Germany (source: kba.de). That represents an increase of 31% compared to the previous year. New registrations of electric passenger cars (BEV) increased disproportionately by 44% to 57,980 units. Significantly, Tesla's Model 3 was the most-registered car in the mid-size segment, while the Porsche Taycan was the most-registered car in the luxury segment - across all drive types. The trend toward electromobility should continue in the coming year. That is also when BYD plans to shake up the market in Europe. As a result, the excitement for shareholders is rising. The same applies to Plug Power and dynaCERT. Both are facing milestones in 2023 that should catapult share prices to new heights.
Read
Commented by Fabian Lorenz on December 14th, 2022 | 12:02 CET
Bayer, BioNTech, Auxico Resources: 200% price gain possible?
With lower than expected inflation in the US, the year-end rally has picked up speed. Could the recession be off after all, or at least short-lived? This would likely boost the stock market in the coming year as well. Today we look at three stocks with potential that benefit from global trends and less from developments in Germany. In the case of Bayer, Bernstein Research has outed itself as a super bull. The global agricultural business should continue to run strong. Auxico Resources is positioning itself as a trader of rare earths and critical raw materials. Revenues are expected to jump significantly in the coming year, and analysts say the stock could triple. BioNTech could finally break out of the sideways trend it has been in since early 2022. The new combination vaccine and the cancer pipeline give hope.
Read
Commented by Fabian Lorenz on December 8th, 2022 | 09:09 CET
Shares: Buy FlatexDegiro now? Uniper gambles, Aspermont before multiplication and Nel ASA?
FlatexDegiro's revenue and profit warning has shocked shareholders. In just three trading days, it went down by about 40%. Is it now worthwhile to enter again? Analysts have a clear opinion. Can the Uniper share price halve? Analysts believe this is possible. In addition, the upcoming Extraordinary General Meeting promises to be exciting. In contrast, the media company and fintech Aspermont is doing well operationally. Therefore, analysts believe that a price multiplication is possible. The share prices of Nel and Plug Power are currently weak. Analysts are confident but currently surprisingly quiet.
Read
Commented by Fabian Lorenz on December 7th, 2022 | 10:46 CET
Bayer, BYD, TubeSolar: Stocks for the year-end rally and beyond?
Investors are currently positioning themselves for the year-end rally. To that end, today, we look at three exciting and very different stocks. BYD has become Tesla's biggest competitor. But the "honeymoon" for electric vehicles in China is coming to an end, analysts say. What is the story? Bayer has increasingly emerged from the shadow of the glyphosate issue this year. Analysts continue to see upside potential for the DAX company. Just like the new German solar hopeful TubeSolar. If the energy turnaround is to succeed, companies like this are needed. After all, the Augsburg-based company is convincing with its innovative technology and could achieve rapid sales growth in the coming years - does this also apply to the share price?
Read
Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET
Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures
Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?
Read